Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 1Glioblastoma 1

Interventions

pembrolizumab 9trastuzumab deruxtecan 5trametinib 4dabrafenib 4zanubrutinib 3nilotinib 3fludarabine 3Trastuzumab 3Dexamethasone 3Cyclophosphamide 3tucatinib 2tisagenlecleucel 2selinexor 2relatlimab 2pemigatinib 2larotrectinib 2ipatasertib 2erdafitinib 2entrectinib 2enfortumab vedotin 2defactinib 2daratumumab 2blinatumomab 2binimetinib 2belzutifan 2axicabtagene ciloleucel 2atezolizumab 2TIC10 compound 2Sunitinib 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × TIC10 compound × Clear all
NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡